Dr Reddy's gets 13 observations from USFDA for Duvvada facility

NEW DELHI: Dr Reddy's Laboratories today said it has received 13 observations from the US health regulator for its formulation manufacturing facility at Duvvada, Visakhapatnam.

"The audit of company's formulation manufacturing facility at Duwada, Visakhapatnam, by the US FDA, has been completed on March 8, 2017. The company have been issued a Form 483 with 13 observations, which the company is addressing," Dr Reddy's Laboratories said in a BSE filing.

The company, however, did not specify the observations.

Shares of Dr Reddy's Laboratories were trading 4.21 per cent lower at Rs 2,731.35 on BSE.

Subscribe ETHealthworld Newsletter

Lyrica, known generically as pregabalin, was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain, which soon became its main market.

With this acquisition, Nephroplus will further strengthen its servicing capacity as the dominant dialysis centre network and will have a presence in 18 states of India with 176 centers across 97 cities.